Latest guidelines for management of DM
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content. Let me synthesize a thorough response from the retrieved textbook material (Harrison's Internal Medicine and emergency medicine sources).
Management of Diabetes Mellitus — Current Guidelines
(Sources: Harrison's Principles of Internal Medicine, 21e; Tintinalli's Emergency Medicine)
1. Goals of Therapy
The overarching goals for all forms of DM are:
- Eliminate symptoms related to hyperglycemia
- Reduce or eliminate long-term microvascular and macrovascular complications
- Allow the patient to achieve as normal a lifestyle as possible
This is best achieved through a multidisciplinary team — primary care physician/endocrinologist, advanced practice provider, pharmacist, certified diabetes educator, nutritionist, behavioral health professional, and relevant subspecialists (ophthalmology, nephrology, cardiology, podiatry, neurology).
2. Glycemic Targets
| Parameter | General Target | Notes |
|---|---|---|
| HbA1c | < 7% | Individualized; < 6.5% in young, newly diagnosed with no CVD; < 8% in elderly/frail/frequent hypoglycemia |
| Fasting plasma glucose | 4.4–7.2 mmol/L (80–130 mg/dL) | |
| Peak postprandial glucose | < 10 mmol/L (< 180 mg/dL) | 1–2 h after meals |
| Time-in-range (TIR) | > 70% | 3.9–10 mmol/L using CGM |
Key principle: Targets are individualized based on age, comorbidities, hypoglycemia risk, disease duration, patient preference, and available resources.
3. Comprehensive Ongoing Care (Surveillance Schedule)
| Domain | Frequency |
|---|---|
| HbA1c | Every 3 months if not at goal; every 6 months if stable |
| Blood pressure | Every visit (2–4×/year) |
| Lipids | 1–2×/year |
| Dilated retinal exam | Annually (or biannually if stable) |
| Foot examination | 1–2×/year by provider; daily by patient |
| Neuropathy screening | Annually |
| Diabetic kidney disease (urine ACR + eGFR) | Annually |
| Dental examination | Twice yearly |
| Immunizations | Influenza, pneumococcal, hepatitis B, COVID-19, RSV (>60 years) |
| Screening for fatty liver disease | If risk factors present (type 2 DM/prediabetes) |
4. Lifestyle Management (Cornerstone for All DM)
Nutrition (Medical Nutrition Therapy — MNT)
- No single ideal diet exists; multiple patterns effective: Mediterranean, DASH, plant-based, low-carbohydrate, low-fat
- Limit simple sugars, fructose, and refined carbohydrates
- Reduce saturated fat; increase dietary fiber
- Weight loss targeted in overweight/obese type 2 DM — even 5% weight loss improves glycemic control
- Caloric deficit of 500–750 kcal/day recommended for weight loss
Physical Activity
- ≥ 150 min/week of moderate-intensity aerobic exercise (e.g., brisk walking)
- Resistance training 2–3×/week
- Avoid prolonged sedentary periods (break every 30 minutes)
- In type 1 DM, balance exercise with carbohydrate intake and insulin adjustments
Psychosocial Care
- Routine screening for depression, anxiety, diabetes distress, disordered eating
- Behavioral health professional involvement when needed
Diabetes Self-Management Education and Support (DSMES)
- Provided at diagnosis, annually, when goals not met, and at life transitions
- Topics: CGM/BGM use, insulin administration, hypoglycemia prevention, foot care, sick-day management
5. Pharmacologic Treatment
Type 2 DM — Step-wise Approach
Step 1 — First-line:
| Drug | Mechanism | Notes |
|---|---|---|
| Metformin | ↓ hepatic glycogenolysis/gluconeogenesis, ↑ insulin sensitivity | First-line; no weight gain, low cost, no hypoglycemia; lowers HbA1c by ~1.5%; contraindicated if eGFR < 30 |
Step 2 — Add second agent (if HbA1c target not met after 3 months, or at initiation in HbA1c ≥ 9%):
Selection guided by comorbidities:
| Comorbidity | Preferred Add-on |
|---|---|
| Established ASCVD or high CV risk | GLP-1 RA (liraglutide, semaglutide) or SGLT-2 inhibitor (empagliflozin, canagliflozin) |
| Heart failure (HFrEF) | SGLT-2 inhibitor (empagliflozin, dapagliflozin) |
| Chronic kidney disease | SGLT-2 inhibitor (if eGFR ≥ 20–25); GLP-1 RA |
| Need for weight loss | GLP-1 RA or SGLT-2 inhibitor |
| Minimize hypoglycemia | DPP-4 inhibitor, GLP-1 RA, SGLT-2 inhibitor |
| Cost constraints | Sulfonylurea or thiazolidinedione |
Drug Class Summary
| Class | Examples | Key Features |
|---|---|---|
| Biguanides | Metformin | First-line; GI side effects; lactic acidosis risk |
| Sulfonylureas | Glipizide, glimepiride | ↑ insulin secretion; hypoglycemia risk; weight gain |
| Thiazolidinediones (TZD) | Pioglitazone, rosiglitazone | Insulin sensitizers; fluid retention; fracture risk; avoid in HF |
| DPP-4 inhibitors | Sitagliptin, saxagliptin | Weight neutral; once daily; no hypoglycemia |
| GLP-1 receptor agonists | Liraglutide, semaglutide, dulaglutide | Weight loss, CV benefit, GI side effects; injectable (or oral semaglutide) |
| SGLT-2 inhibitors | Empagliflozin, dapagliflozin, canagliflozin | Glycosuria; CV and renal protection; risk of DKA, UTI, genital infections |
| Meglitinides | Repaglinide, nateglinide | Postprandial insulin ↑; take with meals |
| α-Glucosidase inhibitors | Acarbose | ↓ carbohydrate absorption; GI side effects |
| Insulin | See below | Required in type 1 DM; used in type 2 when oral agents insufficient |
6. Insulin Therapy
Type 1 DM
- Insulin is mandatory
- Preferred regimen: Basal-bolus (multiple daily injections) or Continuous Subcutaneous Insulin Infusion (CSII/pump)
- Basal: Long-acting (glargine, detemir, degludec) — once or twice daily
- Bolus: Rapid-acting (lispro, aspart, glulisine) — with each meal
- Closed-loop systems (sensor-augmented pumps / hybrid closed-loop) increasingly recommended — automate basal delivery based on CGM readings
Type 2 DM
- Consider insulin when:
- HbA1c > 10% at presentation
- Symptomatic hyperglycemia
- Failure of oral/injectable agents
- Start with basal insulin (glargine or detemir, 10 units/day or 0.1–0.2 units/kg/day) and titrate
- Add prandial (bolus) insulin if postprandial hyperglycemia persists
Insulin Formulations
| Type | Onset | Peak | Duration |
|---|---|---|---|
| Rapid-acting (lispro, aspart) | 5–15 min | 30–90 min | 4–6 h |
| Short-acting (regular) | 30–60 min | 2–3 h | 8–10 h |
| Intermediate (NPH) | 2–4 h | 4–10 h | 10–16 h |
| Long-acting (glargine, detemir) | 2–4 h | No peak | 20–24 h |
| Ultra-long (degludec) | 1 h | No peak | > 42 h |
7. Monitoring
- Continuous Glucose Monitoring (CGM): Preferred for type 1 DM and type 2 DM on basal-bolus insulin; real-time glucose trends and alerts
- Self-monitored blood glucose (SMBG): Fingerstick; useful for type 2 on oral agents
- HbA1c: Reflects mean glucose over ~3 months; test every 3–6 months
- Time-in-Range (TIR): CGM-derived target > 70% of readings in 3.9–10 mmol/L range; < 4% below 3.9 mmol/L
8. Management of Comorbid Conditions
| Condition | Target/Intervention |
|---|---|
| Hypertension | < 130/80 mmHg; ACE inhibitor or ARB first-line (especially with CKD/proteinuria) |
| Dyslipidemia | High-intensity statin for all DM > 40 years or with CV risk; LDL-C < 1.8 mmol/L (< 70 mg/dL) if ASCVD |
| ASCVD | Aspirin 75–100 mg/day (for secondary prevention); GLP-1 RA or SGLT-2 inhibitor |
| CKD | SGLT-2 inhibitor + finerenone (if proteinuria); ACE/ARB; avoid nephrotoxic agents |
| Obesity | GLP-1 RA (semaglutide, tirzepatide); consider metabolic/bariatric surgery (BMI ≥ 35 or ≥ 30 with comorbidities) |
9. Special Situations
Hospitalized Patients
- Target glucose: 7.8–10 mmol/L (140–180 mg/dL) for most critically ill patients
- Use insulin infusion protocols (ICU) or basal-bolus subcutaneous regimens (non-ICU)
- Avoid sole use of sliding-scale insulin
Gestational DM
- First-line: lifestyle and dietary modification
- If targets not met: Insulin (preferred); metformin/glyburide as alternatives
- Targets: Fasting < 5.3 mmol/L; 1-h post-meal < 7.8; 2-h post-meal < 6.7 mmol/L
Elderly Patients
- Less stringent HbA1c goal (7.5–8.5%) to minimize hypoglycemia risk
- Avoid hypoglycemia-prone agents (long-acting sulfonylureas)
- Prefer agents with low hypoglycemia risk (DPP-4 inhibitors, GLP-1 RA)
10. Prevention of Complications
| Complication | Prevention Strategy |
|---|---|
| Retinopathy | Tight glycemic control; annual eye exam |
| Nephropathy | ACE/ARB; SGLT-2 inhibitor; BP control |
| Neuropathy | Glycemic control; foot care; annual monofilament exam |
| Cardiovascular | Statin; ACE/ARB; GLP-1 RA or SGLT-2 inhibitor; aspirin |
| Foot ulcers | Daily inspection; proper footwear; podiatry referral |
Key Take-Home Points:
- Management is individualized and multidisciplinary
- Metformin remains first-line for type 2 DM
- GLP-1 RAs and SGLT-2 inhibitors are preferred add-ons in patients with established ASCVD, HF, or CKD due to cardiovascular and renal outcome benefits
- CGM and closed-loop systems represent the current standard of care in type 1 DM
- Addressing comorbidities (BP, lipids, weight, psychosocial health) is as important as glucose control
— Harrison's Principles of Internal Medicine, 21e (Chapter 416); Tintinalli's Emergency Medicine, 9e (Chapter 115)
This is a shared conversation. Sign in to Orris to start your own chat.